ReviewJournal of diabetes research2015
Diabetic Kidney Disease: Pathophysiology and Therapeutic Targets.
Review in Journal of diabetes research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed, 3 syntheses or guidelines pooled it, 200 citations in OpenAlex.
- Renoprotective effects of the ginger (Zingiber officinale) on Diabetic kidney disease, current knowledge and future direction: a systematic review of animal studies.BMC complementary medicine and therapies · 2022Pooled it
- The effects of omega-3 fatty acids on diabetic nephropathy: A meta-analysis of randomized controlled trials.PloS one · 2020Pooled it
- Sulodexide therapy for the treatment of diabetic nephropathy, a meta-analysis and literature review.Drug design, development and therapy · 2015Pooled it
- A Phase IIb Randomized Controlled Trial Investigating the Effects of Tocotrienol-Rich Vitamin E on Diabetic Kidney Disease.Nutrients · 2021Trial
- Mogroside V Alleviates Renal Injury in Diabetic Mice via Regulation of theInternational journal of molecular sciences · 2026Article
- Functional Molecular Plasma Biomarkers of Inflammation and Repair in Kidney Disease Progression in Gum Arabica Modality of CKD.International journal of molecular sciences · 2026Article
- DOTAP-Based Hybrid Nanostructured Lipid Carriers for CRISPR-Cas9 RNP Delivery TargetingPharmaceutics · 2026Article
- Mining biomarkers for type 2 diabetic nephropathy based on urinary proteomics and metabolomics.Frontiers in endocrinology · 2026Article
- Beyond Traditional Silos: An Integrated Framework Leveraging Novel Pathways for Reducing Cardio-renal Risk in Type 2 Diabetes.Current diabetes reviews · 2026Review
- Intermodulation of endoplasmic reticulum stress and ferroptosis in diabetic nephropathy: molecular mechanisms and therapeutic potentials.Apoptosis : an international journal on programmed cell death · 2025Review
- DeSUMOylation of RBMX regulates exosomal sorting of cargo to promote renal tubulointerstitial fibrosis in diabetic kidney disease.Journal of advanced research · 2025Article
- Microvascular Dysfunction Following Cardioplegic Arrest and Cardiopulmonary Bypass: Impacts of Diabetes and Hypertension.Biomedicines · 2025Review
- Insights into the Novel Biomarkers Expressed in Diabetic Nephropathy: Potential Clinical Applications.Current pharmaceutical design · 2025Review
- Advances in Traditional Chinese Medicine research in diabetic kidney disease treatment.Pharmaceutical biology · 2024Review
- Circ-Luc7l Absence Attenuates Diabetic Nephropathy Progression by Reducing Mesangial Cell Excessive Proliferation, Inflammation, and Extracellular Matrix Accumulation via Mediating the miR-205-5p/Tgfbr1 Pathway.Biochemical genetics · 2024Article
- New perspectives in the management of diabetic nephropathy.World journal of diabetes · 2024Article
- CircACTR2 attenuated the effects of tetramethylpyrazine on human kidney cell injury.Journal of bioenergetics and biomembranes · 2024Article
- The effect of incretin-based drugs on the riks of acute pancreatitis: a review.Journal of diabetes and metabolic disorders · 2024Review
- Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International journal of molecular sciences · 2024Review
- Type 2 Diabetes and Chronic Kidney Disease: An Opportunity for Pharmacists to Improve Outcomes.Journal of clinical medicine · 2024Review
30 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes is a worldwide epidemic that has led to a rise in diabetic kidney disease (DKD). Over the past two decades, there has been significant clarification of the various pathways implicated in the pathogenesis of DKD. Nonetheless, very little has changed in the way clinicians manage patients with this disorder. Indeed, treatment is primarily centered on controlling hyperglycemia and hypertension and inhibiting the renin-angiotensin system. The purpose of this review is to describe the current understanding of how the hemodynamic, metabolic, inflammatory, and alternative pathways are all entangled in pathogenesis of DKD and detail the various therapeutic targets that may one day play a role in quelling this epidemic.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.